Table 2.
Testing results stratified by concomitant immunosuppressive therapy
| HACAs | Therapeutic IFX | Non-therapeutic IFX | Non-interpretable | |
|---|---|---|---|---|
| Concurrent IS (n=69) | 10 (14) | 33 (48) | 22 (32) | 4 (6) |
| No concurrent IS (n=86) | 25 (29) | 18 (21) | 41 (48) | 2 (2) |
HACAs, human anti-chimeric antibodies; IFX, infliximab; IS, immunosuppressive therapy.